TABLE 1.

Demographic characteristics of subjects in the study of inactivated SARS‐CoV‐2 vaccination

	Healthy subjects	AR patients	p‐Value
Total subjects, n	25	32	–
Gender, male/female	9/16	11/21	.899
Age (years)	24 (23, 27)	24 (22, 26)	.197
Body mass index	21.1 (19.1, 22.3)	20.8 (19.2, 22.4)	.908
Patients with asthma, n (%)	0	1 (3.1%)	1.000
Patients with atopic eczema, n (%)	0	1 (3.1%)	1.000
Sensitization pattern, n (%)
Dermatophagoides pteronyssinus	0	30 (94.8%)
Dermatophagoides farinae	0	30 (94.8%)
Cockroach	0	2 (6.4%)
Cat dander	0	5 (15.6%)
Dog dander	0	4 (12.5%)
Artemisia	0	1 (3.1%)
Platanus	0	1 (3.1%)
Alternaria	0	3 (9.4%)
VAS symptom score	0 (0, 0)	5.0 (3.3, 7.0)	<.001

Note: For continuous variables, data are expressed as medians and interquartile ranges.

Abbreviations: AR, allergic rhinitis; VAS, visual analogue scale.